IMA NASDAQ
ImageneBio Inc
1W: -6.5%
1M: -6.8%
3M: -3.8%
YTD: -17.0%
1Y: -67.3%
3Y: -92.5%
5Y: -96.5%
$5.76
+0.16 (+2.86%)
Weekly Expected Move ±8.0%
$5
$5
$6
$6
$6
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$65.0M
52W Range3.94-17.96
Volume3,405
Avg Volume25,261
Beta0.73
Dividend—
Analyst Ratings
Company Info
CEOKristin Yarema
Employees17
SectorHealthcare
IndustryBiotechnology
IPO Date1998-02-27
Websiteinmagenebio.com
12526 High Bluff Drive, Suite 345, San Diego, CA 92130
San Diego, CA 92130
US
San Diego, CA 92130
US
858 345 6265
About ImageneBio Inc
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.
Latest News
Lupin Announces the Approval of Diazepam Injection, USP in the United States
KUBTEC® Announces Europe's First PICASSO® Plus Installation at Falun Hospital in Sweden
KUBTEC® annonce la première installation du système PICASSO® Plus en Europe, à l'hôpital de Falun, en Suède
KUBTEC® anuncia la primera instalación de PICASSO® Plus en Europa en el hospital Falun de Suecia
KUBTEC® gibt die europaweit erste Installation des PICASSO® Plus im Krankenhaus in Falun, Schweden, bekannt
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Yarema Kristin | M-Exempt | 38,376 | — | 2026-07-25 |
| Yarema Kristin | J-Other | 115,129 | — | 2026-07-25 |
| Yarema Kristin | M-Exempt | 38,376 | — | 2026-07-25 |
| Yarema Kristin | J-Other | 115,129 | — | 2026-07-25 |
| Grant-Huerta Yanina | 0 | — | 2026-07-20 |